Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
View ORCID ProfileLeticia Monin-Aldama, View ORCID ProfileAdam G. Laing, View ORCID ProfileMiguel Muñoz-Ruiz, View ORCID ProfileDuncan R McKenzie, View ORCID ProfileIrene del Molino del Barrio, View ORCID ProfileThanussuyah Alaguthurai, View ORCID ProfileClara Domingo-Vila, View ORCID ProfileThomas S. Hayday, Carl Graham, View ORCID ProfileJeffrey Seow, Sultan Abdul-Jawad, View ORCID ProfileShraddha Kamdar, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, View ORCID ProfileJennifer Vidler, Helen Kakkassery, Sinha Shubhankar, View ORCID ProfileRichard Davis, Liane Dupont, View ORCID ProfileIsaac Francos Quijorna, Puay Lee, Josephine Eum, Maria Conde Poole, View ORCID ProfileMagdalene Joseph, Daniel Davies, View ORCID ProfileYin Wu, View ORCID ProfileAna Montes, Mark Harries, View ORCID ProfileAnne Rigg, View ORCID ProfileJames Spicer, View ORCID ProfileMichael H Malim, View ORCID ProfilePaul Fields, View ORCID ProfilePiers Patten, View ORCID ProfileFrancesca Di Rosa, View ORCID ProfileSophie Papa, View ORCID ProfileTim Tree, View ORCID ProfileKatie Doores, View ORCID ProfileAdrian C. Hayday, View ORCID ProfileSheeba Irshad
doi: https://doi.org/10.1101/2021.03.17.21253131
Leticia Monin-Aldama
1The Francis Crick Institute, London, UK
Adam G. Laing
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Miguel Muñoz-Ruiz
1The Francis Crick Institute, London, UK
Duncan R McKenzie
1The Francis Crick Institute, London, UK
Irene del Molino del Barrio
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
3UCL Cancer Institute, University College London, London, UK
Thanussuyah Alaguthurai
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
5Breast Cancer Now Research Unit, King’s College London, London, UK
Clara Domingo-Vila
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Thomas S. Hayday
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Carl Graham
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
Jeffrey Seow
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
Sultan Abdul-Jawad
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
Shraddha Kamdar
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Elizabeth Harvey-Jones
5Breast Cancer Now Research Unit, King’s College London, London, UK
Rosalind Graham
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
Jack Cooper
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Muhammad Khan
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Jennifer Vidler
8Department of Haematological Medicine, King’s College Hospital, London, UK
Helen Kakkassery
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
Sinha Shubhankar
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
Richard Davis
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Liane Dupont
5Breast Cancer Now Research Unit, King’s College London, London, UK
Isaac Francos Quijorna
9Regeneration Group, Wolfson Centre for Age-Related Diseases, IoPPN, King’s College London, London, UK
Puay Lee
1The Francis Crick Institute, London, UK
Josephine Eum
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Maria Conde Poole
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Magdalene Joseph
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Daniel Davies
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Yin Wu
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
Ana Montes
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Mark Harries
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Anne Rigg
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
James Spicer
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Michael H Malim
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
Paul Fields
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
8Department of Haematological Medicine, King’s College Hospital, London, UK
Piers Patten
1The Francis Crick Institute, London, UK
8Department of Haematological Medicine, King’s College Hospital, London, UK
Francesca Di Rosa
10Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy
Sophie Papa
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Tim Tree
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Katie Doores
6Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
Adrian C. Hayday
1The Francis Crick Institute, London, UK
2Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UK
Sheeba Irshad
4Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
5Breast Cancer Now Research Unit, King’s College London, London, UK
7Guy’s and St Thomas’ NHS Foundation Trust, London, UK
11Cancer Research UK (CRUK) Clinician Scientist, London, UK
Article usage
Posted March 17, 2021.
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
Leticia Monin-Aldama, Adam G. Laing, Miguel Muñoz-Ruiz, Duncan R McKenzie, Irene del Molino del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, Thomas S. Hayday, Carl Graham, Jeffrey Seow, Sultan Abdul-Jawad, Shraddha Kamdar, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, Jennifer Vidler, Helen Kakkassery, Sinha Shubhankar, Richard Davis, Liane Dupont, Isaac Francos Quijorna, Puay Lee, Josephine Eum, Maria Conde Poole, Magdalene Joseph, Daniel Davies, Yin Wu, Ana Montes, Mark Harries, Anne Rigg, James Spicer, Michael H Malim, Paul Fields, Piers Patten, Francesca Di Rosa, Sophie Papa, Tim Tree, Katie Doores, Adrian C. Hayday, Sheeba Irshad
medRxiv 2021.03.17.21253131; doi: https://doi.org/10.1101/2021.03.17.21253131
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
Leticia Monin-Aldama, Adam G. Laing, Miguel Muñoz-Ruiz, Duncan R McKenzie, Irene del Molino del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, Thomas S. Hayday, Carl Graham, Jeffrey Seow, Sultan Abdul-Jawad, Shraddha Kamdar, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, Jennifer Vidler, Helen Kakkassery, Sinha Shubhankar, Richard Davis, Liane Dupont, Isaac Francos Quijorna, Puay Lee, Josephine Eum, Maria Conde Poole, Magdalene Joseph, Daniel Davies, Yin Wu, Ana Montes, Mark Harries, Anne Rigg, James Spicer, Michael H Malim, Paul Fields, Piers Patten, Francesca Di Rosa, Sophie Papa, Tim Tree, Katie Doores, Adrian C. Hayday, Sheeba Irshad
medRxiv 2021.03.17.21253131; doi: https://doi.org/10.1101/2021.03.17.21253131
Subject Area
Subject Areas
- Addiction Medicine (576)
- Allergy and Immunology (867)
- Anesthesia (306)
- Cardiovascular Medicine (4480)
- Dermatology (385)
- Emergency Medicine (614)
- Epidemiology (15276)
- Forensic Medicine (31)
- Gastroenterology (1133)
- Genetic and Genomic Medicine (6643)
- Geriatric Medicine (671)
- Health Economics (1006)
- Health Informatics (4602)
- Health Policy (1378)
- Hematology (544)
- HIV/AIDS (1275)
- Medical Education (626)
- Medical Ethics (147)
- Nephrology (674)
- Neurology (6692)
- Nursing (346)
- Nutrition (1006)
- Obstetrics and Gynecology (1152)
- Oncology (3369)
- Ophthalmology (988)
- Orthopedics (370)
- Otolaryngology (421)
- Pain Medicine (437)
- Palliative Medicine (131)
- Pathology (668)
- Pediatrics (1703)
- Primary Care Research (717)
- Public and Global Health (9284)
- Radiology and Imaging (2223)
- Respiratory Medicine (1201)
- Rheumatology (598)
- Sports Medicine (535)
- Surgery (720)
- Toxicology (100)
- Transplantation (290)
- Urology (266)